FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
First Genetic-Based Breast Cancer Risk Test Enters International Market
March 15th, 2007
InterGenetics, a predictive medicine company, focused on molecular diagnostics and targeted therapy for cancer, announced the international release of the first genetic-based, breast cancer risk test that incorporates both personal history and gene-based information to determine a woman's future breast cancer risk. Opaldia, a genetic health service provider with a network of clinics, will release OncoVue(R) in the United Kingdom and Ireland under an exclusive agreement. "OncoVue has undergone over 7 years of research, and the genetic information for this test came from the testing of over 8,000 women with and without breast cancer from 5 geographic regions of the United...
Source: FDA Law Weekly (2007-03-15)
|
